Search
-
GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™
Media
the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC).
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-unanimous-fda-panel-approval-recommendation-for-votrient/
First published: 05 October 2009
-
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
Media
GSK announced the U.S. FDA has approved Votrient for the treatment of soft tissue sarcoma who have received prior chemotherapy.
https://www.gsk.com/en-gb/media/press-releases/fda-approves-votrient-for-treatment-of-patients-with-certain-types-of-advanced-soft-tissue-sarcoma/
First published: 26 April 2012
-
FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer
Media
GSK announced that FDA has approved Votrient to treat patients with advanced renal cell carcinoma (RCC).
https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-votrient-for-advanced-renal-cell-cancer/
First published: 19 October 2009